Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
150%(3 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_3
3
75%
Ph not_applicable
1
25%

Phase Distribution

0

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Phase 3Large-scale testing
3(75.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(2)
Terminated(1)
Other(1)

Detailed Status

Completed2
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 33 (75.0%)
N/A1 (25.0%)

Trials by Status

completed250%
terminated125%
unknown125%

Recent Activity

0 active trials
Showing 4 of 4
unknownnot_applicable

Effectiveness of Photodynamic Therapy in the Disinfection of Root Canals in Patients With Apical Lesion

NCT05916859
terminatedphase_3

An Efficacy and Safety Study of Ustekinumab in Participants With Active Nonradiographic Axial Spondyloarthritis

NCT02407223
completedphase_3

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

NCT01369342
completedphase_3

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

NCT01369329

Clinical Trials (4)

Showing 4 of 4 trials
NCT05916859Not Applicable

Effectiveness of Photodynamic Therapy in the Disinfection of Root Canals in Patients With Apical Lesion

Unknown
NCT02407223Phase 3

An Efficacy and Safety Study of Ustekinumab in Participants With Active Nonradiographic Axial Spondyloarthritis

Terminated
NCT01369342Phase 3

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Completed
NCT01369329Phase 3

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4